


Searching News Database: candidiasis
HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
HSMN NewsFeed - 18 Jan 2024
Cepheid Receives Expanded FDA Clearance with CLIA Waiver for Xpert(R) Xpress MVP
Cepheid Receives Expanded FDA Clearance with CLIA Waiver for Xpert(R) Xpress MVP
HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
HSMN NewsFeed - 14 Jun 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
HSMN NewsFeed - 16 Aug 2017
Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog(R) II Cream
Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog(R) II Cream
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 20 Sep 2013
RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma
RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma
HSMN NewsFeed - 19 Feb 2013
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
HSMN NewsFeed - 16 Dec 2008
Generex Biotechnology and Pevion Biotech Announce Plans for Immunotherapeutic Vaccine Collaboration
Generex Biotechnology and Pevion Biotech Announce Plans for Immunotherapeutic Vaccine Collaboration
HSMN NewsFeed - 28 Jul 2008
Barrier Therapeutics Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis
Barrier Therapeutics Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis
HSMN NewsFeed - 16 Jul 2008
BioAlliance Pharma suspends the Phase II/III trial of doxorubicin Transdrug(R) in primary liver cancer
BioAlliance Pharma suspends the Phase II/III trial of doxorubicin Transdrug(R) in primary liver cancer
HSMN NewsFeed - 8 Jul 2008
Stiefel Laboratories, Inc. Commences Tender Offer to Acquire Barrier Therapeutics, Inc.
Stiefel Laboratories, Inc. Commences Tender Offer to Acquire Barrier Therapeutics, Inc.
HSMN NewsFeed - 23 Jun 2008
Barrier Therapeutics, Inc. and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Barrier Therapeutics, Inc. and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
HSMN NewsFeed - 23 Jun 2008
BioAlliance Pharma extends its Loramyc(TM) License to China with NovaMed Pharmaceuticals
BioAlliance Pharma extends its Loramyc(TM) License to China with NovaMed Pharmaceuticals
HSMN NewsFeed - 7 May 2008
Astellas' Mycamine(R) (micafungin) Licensed for Use in Europe to Treat Serious Fungal Infections
Astellas' Mycamine(R) (micafungin) Licensed for Use in Europe to Treat Serious Fungal Infections
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 26 Mar 2008
BioAlliance Pharma Receives Market Approval for Loramyc(R) in Germany, Belgium and Luxemburg
BioAlliance Pharma Receives Market Approval for Loramyc(R) in Germany, Belgium and Luxemburg
HSMN NewsFeed - 9 Jan 2008
BioAlliance Pharma Receives Market Approval for Loramyc(R) in the United Kingdom and Denmark
BioAlliance Pharma Receives Market Approval for Loramyc(R) in the United Kingdom and Denmark
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
HSMN NewsFeed - 12 Jul 2007
Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
HSMN NewsFeed - 3 Jul 2007
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc(TM) From BioAlliance Pharma
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc(TM) From BioAlliance Pharma
HSMN NewsFeed - 14 Jun 2007
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
HSMN NewsFeed - 16 May 2007
Barrier Therapeutics Appoints Dr. Braham Shroot, Dermatology Expert, as New Chief Scientific Officer
Barrier Therapeutics Appoints Dr. Braham Shroot, Dermatology Expert, as New Chief Scientific Officer
HSMN NewsFeed - 3 May 2007
Barrier Therapeutics Receives FDA Approval for Solagé(R) Topical Solution Labeling Expansion
Barrier Therapeutics Receives FDA Approval for Solagé(R) Topical Solution Labeling Expansion
HSMN NewsFeed - 8 Mar 2007
Barrier Therapeutics Receives Regulatory Approval to Market Xolegel(TM) in Canada
Barrier Therapeutics Receives Regulatory Approval to Market Xolegel(TM) in Canada
HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
HSMN NewsFeed - 5 Dec 2006
Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce Out-licensing of Aminocandin Anti-fungal
Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce Out-licensing of Aminocandin Anti-fungal
HSMN NewsFeed - 13 Oct 2006
BioAlliance Pharma Receives Marketing Authorisation for Its First Product, Loramyc(R)
BioAlliance Pharma Receives Marketing Authorisation for Its First Product, Loramyc(R)
HSMN NewsFeed - 17 Jul 2006
BioAlliance Pharma Strengthens International Capabilities in Key Legal, IP and Regulatory Departments
BioAlliance Pharma Strengthens International Capabilities in Key Legal, IP and Regulatory Departments
HSMN NewsFeed - 26 Jun 2006
BioAlliance Pharma Strengthens Operational Management Ahead of Loramyc(R) Launch
BioAlliance Pharma Strengthens Operational Management Ahead of Loramyc(R) Launch
HSMN NewsFeed - 16 May 2006
BioAlliance Pharma Boosts Business Development Operations in Europe and US
BioAlliance Pharma Boosts Business Development Operations in Europe and US
Additional items found! 73
Members Archive contains
73 additional stories matching:
candidiasis
(Password required)
candidiasis
(Password required)
